查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836843

按產品、成像方式、應用和最終用戶分類的臨床前成像市場 - 全球預測 2025-2032

Preclinical Imaging Market by Product, Type, Imaging Modality, Applications, End Users - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年臨床前影像市場將成長至 54.9 億美元，複合年成長率為 5.07%。

主要市場統計數據
基準年2024年 36.9億美元
預計2025年 38.7億美元
預測年份：2032年 54.9億美元
複合年成長率（%） 5.07%

簡明介紹臨床前影像促進因素以及儀器、試劑和軟體相關人員的策略重點

在技​​術融合、試劑功能擴展以及終端用戶需求不斷變化等因素的推動下，臨床前成像領域正在快速發展。本執行摘要總結了影響臨床前研究儀器供應商、試劑開發商、軟體供應商和研究買家的當代動態。在這種情況下，領導者必須協調科學研究動態與營運現實，例如實驗室工作流程整合、轉化研究的監管協調以及日益成長的多模態資料協調需求。

以下章節將重點放在策略曲折點，而非靜態指標。讀者將獲得不同模式變革的分析、2025年關稅相關影響對美國供應鏈的評估，以及闡明誰購買什麼、為什麼購買的可操作細分洞察。報告旨在為決策者提供結構化的觀點，以優先考慮投資、加速商業化並最佳化夥伴關係關係。本報告重點關注對採購、開發平臺和轉換應用的實際影響，為提出有針對性的建議和支持每個結論的嚴謹方法奠定了基礎。

多模態融合、試劑專業化、進階分析、監管協調和協作模型如何重新定義臨床前成像

過去五年，臨床前影像技術經歷了數次變革，正逐漸成為轉化科學的核心組成部分。融合解剖學、功能學和分子學讀數的多模態平台正在減少跨平台數據整合的阻力，並縮短臨床前決策週期。其次，試劑正變得更加專業化和應用主導，造影劑和示踪劑的設計旨在檢測特定的生物通道。

第三，先進的影像處理、人工智慧驅動的分割技術以及定量放射組學技術正在實現更豐富的表現型表徵。第四，監管預期正轉向統一的成像生物標記驗證方法，鼓勵開發商和監管機構更早開展合作。最後，共同研究模式正在不斷發展。學術實驗室、合約研究組織 (CRO) 和產業合作夥伴擴大採用聯盟式研究和共用基礎設施，以分攤成本並加速可重複性。總而言之，這些轉變正在重新定義整個生態系統的競爭優勢和營運韌性。

評估2025年關稅對供應鏈中斷和策略採購回應的影響，以因應採購和專案連續性

2025年美國關稅調整已在全球臨床前成像相關供應鏈中造成了顯著的摩擦，影響了採購計劃、零件採購以及進口設備和試劑的成本結構。先前依賴即時進口的供應商面臨前置作業時間延長和到岸成本上升的問題，迫使一些供應商重新評估其採購區域和庫存政策。為此，一些製造商加快了供應商多元化，並增加了區域組裝，以保護客戶免受關稅波動的影響。

此外，由於採購團隊力求在儀器升級與耗材及服務合約相關的營運支出之間取得平衡，客戶的資本投資決策也經歷了重新排序。關稅環境也引發了長期供應協議的談判，並激發了人們對區域製造夥伴關係的興趣。重要的是，關稅的影響因產品類型而異。高價值、低產量的儀器與對單位成本變化敏感的試劑含量高的耗材相比，需要不同的緩解策略。因此，積極審查籌資策略並與供應鏈團隊合作模擬關稅情景的相關人員，能夠更好地保持測試的連續性並滿足轉換專案進度。

將產品類型、系統類型、模式、應用和最終用戶優先順序與策略定位連結的多維細分框架

精細的細分視角揭示了臨床前影像市場創新和商業性焦點的集中。試劑包括生物發光成像試劑、螢光成像試劑、MRI造影追蹤劑、超音波造影試劑和 X光 CT造影試劑等類別。這些頻譜驅動著特定於成像模式的工作流程，並決定了耗材的成本概況、保存期限和合規性。同時，軟體和服務為影像重建、定量分析和資料管理提供了運算基礎，通常以雲端訂閱服務的形式打包。

從類型上看，生態系統的特點是分為多模態和獨立成像系統，多模態配置提供整合的工作流程以減少跨平台差異，而獨立系統提供集中的功能和較小的資本佔用。成像顯像模式進一步分為磁粒子成像、磁振造影、微型電腦斷層掃描、光學成像、正子斷層掃描和單光子發射電腦斷層掃描，每種模式在靈敏度、空間解析度和示蹤劑相容性方面都有不同的權衡，從而影響研究設計。

心臟病學、藥物開發、免疫學/發炎、感染疾病、神經病學和腫瘤學各自都有其獨特的終點定義、吞吐量預期和驗證需求，推動了技術要求和採購邏輯。學術和研究機構優先考慮靈活性和方法透明度；受託研究機構重視吞吐量、可重複性和監管級文件；製藥生物技術公司則強調轉化相關性、與臨床生物標記的數據整合以及供應商課責。整合這些細分層面，為產品定位、商業化策略和研發投資優先順序提供了一個細緻的架構。

美洲、歐洲、中東和非洲以及亞太地區的商業化動態和差異化的招募管道將塑造打入市場策略

區域動態將顯著影響臨床前影像的商業化路徑和策略重點。在美洲，對轉化研究基礎設施的投資和密集的生物技術中心網路正在刺激對高性能、受監管服務和高級分析的需求，供應商優先考慮其服務的可靠性和檢驗。同時，歐洲、中東和非洲是一個多元化的地區，其多樣化的監管環境和多樣化的醫療保健資金籌措模式需要靈活的商業策略，因此互通性和本地監管指導對於應用至關重要。

在亞太地區，快速提升的研究能力和不斷擴展的臨床測試活動正在推動對可擴展系統和經濟高效耗材的需求，而本地製造夥伴關係和產學研合作則正在加速技術應用。在這些全部區域，人事費用、監管時間表和基礎設施成熟度的差異，為多模態平台和獨立系統創造了獨特的應用曲線，決定了企業優先考慮現場測試、夥伴關係和本地化支援網路。了解這些區域概況對於制定銷售策略、客戶教育計畫和售後服務模式至關重要。

競爭優勢源自模組化硬體、試劑準確性、檢驗的分析以及促進客戶維繫的整合服務模式

關鍵的公司層面洞察揭示了策略選擇如何體現在產品系列、市場進入方式和夥伴關係模式中。領先的儀器供應商正在投資模組化架構，以實現增量升級和多模態整合，在保護客戶資本的同時實現功能擴展。試劑開發人員正專注於開發高特異性的造影劑和放射性示踪劑，以提高穩定性和批次一致性，並認知到買家信心越來越依賴可重複性和監管文件。

軟體和分析公司正透過檢驗的演算法、透明的效能指標以及與常見實驗室資訊管理系統的互通性來脫穎而出。在商業性方面，一些公司正在擴展其服務產品，包括應用支援、成像生物標記鑑定和承包測試執行，以吸引尋求單一來源責任制的申辦方。硬體供應商、試劑供應商和分析供應商之間的策略夥伴關係正變得越來越普遍，從而實現了配套服務，降低了最終用戶的整合風險。最終，那些將技術藍圖與最終用戶工作流程和監管期望相結合的公司將獲得更牢固的公司間關係和長期合約。

為供應商和買家提供可行的策略重點，以增強供應彈性、模組化整合、監管協調和夥伴關係主導的採用

產業領導者可以透過採取一系列注重彈性、協作和以客戶為中心的設計，加速其影響力。首先，重新思考您的供應鏈架構，納入雙重採購、區域組裝和安全庫存實踐，以減輕貿易中斷和零件短缺對您營運的影響。其次，優先考慮模組化產品藍圖和開放整合標準，以減少客戶鎖定障礙，並實現符合您實驗室需求的無縫多模態工作流程。

第三，投資法規和驗證支援服務，幫助客戶將臨床前影像生物標記轉化為臨床相關的終點。第四，設計商業模式，將資本彈性與以結果為導向的服務等級結合，以適應不同的買家風險狀況。第五，與學術中心和合約研究組織 (CRO) 建立夥伴關係，共同開發通訊協定並產生可重複的證據來支持商業性主張。透過實施這些有針對性的措施，組織可以增強競爭優勢，保護業務連續性，並加速整個生態系統的技術應用。

我們的混合方法結合了專家訪談、技術基準化分析和三重二手資訊，以提供可行的見解。

支撐本分析的調查方法融合了質性專家訪談、技術基準化分析和三角二次研究，以確保堅實的實證基礎。包括儀器工程師、試劑化學家、成像科學家和採購負責人在內的領域專家，對特定於模式的權衡取捨和採用促進因素進行了解讀。技術基準測試比較了系統規格、試劑配置和分析能力，以識別趨同和分化的模式。

二級資訊來源包括同行評審文獻、臨床轉換用例、監管指南文件以及製造商發布的技術規範，這些資料被整合在一起，用於檢驗趨勢並確定共識領域和新興討論領域。在此過程中，研究結果與從業人員的回饋進行交叉引用，以期為檢測設計、採購和商業化提供實際指導。這種混合方法在技術嚴謹性與市場相關性之間取得平衡，為本簡報中提出的可行建議奠定了基礎。

綜合可行的結論，結合技術融合、營運彈性和監管協調，推動轉化臨床前影像

最後，臨床前成像正處於關鍵的十字路口，技術成熟度、試劑複雜性和先進分析技術將匯聚一堂，加速轉化效應。隨著生態系統向整合化、可重複的工作流程轉變，透過策略性供應鏈重新設計、模組化技術採用和強化驗證管道進行調整的相關人員將獲得巨大的價值。此外，地區差異凸顯了製定尊重監管多樣性和營運現實的客製化商業化策略的必要性。

隨著市場的發展，那些將科學創新與切實可行的商業化實踐（例如可擴展的服務交付、夥伴關係主導的方案製定以及清晰的監管合作計劃）相結合的組織，將引領技術應用並與最終用戶保持長期合作關係。本文提出的見解旨在為此類策略選擇提供參考，並為直接採取行動以保障研究的連續性並提升轉化成果奠定基礎。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 整合人工智慧，實現臨床前 MRI 中的自動病變檢測和生物標記提取
  • 開發用於小動物模型即時血管評估的高速體積超音波影像系統
  • 採用混合 PET/MRI 平台在腫瘤學研究中同時進行功能與解剖影像
  • 使用造影進行 3D 微型 CT 成像以在囓齒動物模型中進行縱向骨骼密度和血管研究
  • 螢光分子斷層掃描技術的進步使得深層組織成像和定量螢光探針分析成為可能
  • 光超音波成像合併超音波動態監測腫瘤氧合及血管變化
  • 影像擷取通訊協定和數據規範化工作流程的標準化，以提高臨床前實驗室的可重複性

第6章 2025年美國關稅的累積影響

第7章 人工智慧的累積影響，2025年

8. 臨床前影像市場（按產品）

  • 試劑
    • 生物發光成像試劑
    • 螢光成像試劑
    • MRI造影劑
    • PET放射性追蹤劑
    • 超音波造影劑
    • X光CT造影劑
  • 軟體和服務

9. 臨床前影像市場（按類型）

  • 多模態系統
  • 獨立成像系統

10. 臨床前影像市場（依影像方式）

  • 磁粒子成像
  • 磁振造影
  • 微電腦電腦斷層掃描
  • 光學成像
  • 正子斷層掃描
  • 單光子發射電腦斷層掃描

第11章臨床前影像市場（按應用）

  • 心臟病學
  • 藥物開發
  • 免疫學和炎症
  • 感染疾病
  • 神經病學
  • 腫瘤學

12. 臨床前影像市場（依最終使用者）

  • 學術研究機構
  • 合約研究組織
  • 製藥和生物技術公司

13. 臨床前影像市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

14. 臨床前影像市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 臨床前影像市場（按國家/地區）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Advanced Molecular Vision, Inc.
    • Agilent Technologies, Inc.
    • Angstrom Advanced Inc.
    • Aspect Imaging Ltd.
    • AXT Pty Ltd
    • Berthold Technologies
    • Bruker Corporation
    • Cubresa, Inc.
    • Euro-BioImaging ERIC
    • FUJIFILM Holdings America Corporation
    • GE HealthCare Technologies Inc.
    • IVIM Technology Corp.
    • KUB Technologies, Inc.
    • LI-COR, Inc.
    • Mediso Ltd.
    • Milabs BV
    • Miltenyi BIoTec GmbH
    • MR Solutions Ltd.
    • Peira bvba
    • PerkinElmer Inc.
    • Revvity, Inc.
    • Scitech Pty Ltd
    • Siemens AG
    • TriFoil Imaging
    • United Imaging Healthcare Co., Ltd.
Product Code: MRR-030EE48515D3

The Preclinical Imaging Market is projected to grow by USD 5.49 billion at a CAGR of 5.07% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.69 billion
Estimated Year [2025] USD 3.87 billion
Forecast Year [2032] USD 5.49 billion
CAGR (%) 5.07%

A concise orientation to contemporary preclinical imaging drivers and strategic priorities for instrument, reagent, and software stakeholders

The preclinical imaging landscape is rapidly advancing, driven by technology convergence, expanding reagent capabilities, and evolving end-user demands. This executive summary synthesizes contemporary dynamics affecting instrument vendors, reagent developers, software providers, and institutional buyers engaged in preclinical research. Within this context, leaders must reconcile scientific opportunity with operational realities such as laboratory workflow integration, regulatory alignment for translational studies, and the rising imperative for multimodal data harmonization.

Throughout the following sections, the narrative emphasizes strategic inflection points rather than static metrics. Readers will find an analysis of transformative shifts across modalities, an assessment of tariff-related impacts on the U.S. supply chain in 2025, and actionable segmentation insight that clarifies who buys what, and why. The intent is to furnish decision-makers with a structured perspective for prioritizing investment, accelerating commercialization pathways, and optimizing partnerships. By focusing on practical implications for procurement, development pipelines, and translational adoption, this introduction sets the stage for targeted recommendations and a rigorous methodology that underpins each conclusion.

How multimodal convergence, reagent specialization, advanced analytics, regulatory harmonization, and collaborative models are redefining preclinical imaging

The past five years have seen several transformative shifts that are reshaping preclinical imaging as a core enabler for translational science. First, instrumentation convergence has accelerated; multimodal platforms that combine anatomical, functional, and molecular readouts are reducing the friction of cross-platform data integration, thereby shortening preclinical decision cycles. Second, reagents are becoming more specialized and application-driven, with contrast agents and tracers designed to interrogate discrete biological pathways, which in turn informs more precise study designs and endpoint selection.

Third, software and analytics have moved from optional add-ons to critical differentiators, as advanced image processing, AI-driven segmentation, and quantitative radiomics enable richer phenotypic characterization. Fourth, regulatory expectations are shifting toward harmonized validation approaches for imaging biomarkers, prompting earlier engagement between developers and regulators. Finally, collaboration models are evolving: academic laboratories, CROs, and industry partners increasingly adopt consortium-based studies and shared infrastructure to distribute cost and accelerate reproducibility. Taken together, these shifts are redefining competitive advantage and operational resiliency across the ecosystem.

Assessment of 2025 tariff-induced supply chain disruptions and strategic sourcing responses that influenced procurement and program continuity

The U.S. tariff adjustments implemented in 2025 introduced measurable friction across global supply chains relevant to preclinical imaging, affecting procurement timelines, component sourcing, and cost structures for imported instrumentation and reagents. Vendors that previously relied on just-in-time imports encountered increased lead times and higher landed costs, prompting several to reassess sourcing geographies and inventory policies. In response, some manufacturers accelerated diversification of supplier bases and increased regional assembly to insulate clients from tariff volatility.

Furthermore, customers experienced a re-prioritization of capital expenditure decisions as procurement teams sought to balance equipment upgrades with operational expenditures tied to consumables and service contracts. The tariff environment also catalyzed negotiations on long-term supply agreements and stimulated interest in regional manufacturing partnerships. Importantly, the tariff impact differed across product categories; high-value, low-volume instruments presented different mitigation options than reagent-heavy consumable flows, which are more sensitive to per-unit cost changes. As a result, stakeholders that proactively revised sourcing strategies and engaged supply chain teams to model tariff scenarios were better positioned to maintain study continuity and protect timelines for translational programs.

A multidimensional segmentation framework linking product categories, system types, modalities, applications, and end-user priorities to strategic positioning

A granular segmentation lens clarifies where innovation and commercial focus are concentrated across the preclinical imaging landscape. By product, the market differentiates between Reagents and Software & Services, where Reagents encompass categories such as bioluminescent imaging reagents, fluorescent imaging reagents, MRI contrasting reagents, PET radioactive tracers, ultrasound contrasting reagents, and X-ray CT contrasting reagents; this spectrum drives modality-specific workflows and dictates consumable cost profiles, shelf-life considerations, and regulatory handling. In parallel, Software & Services deliver the computational backbone for image reconstruction, quantitative analysis, and data management, increasingly packaged as cloud-enabled, subscription-based services.

By type, the ecosystem is characterized by a split between multimodal systems and standalone imaging systems, with multimodal configurations offering integrated workflows that reduce cross-platform variability while standalone systems provide focused capability and lower capital footprints. Imaging modality further stratifies the landscape into magnetic particle imaging, magnetic resonance imaging, micro-computed tomography, optical imaging, positron emission tomography, and single-photon emission computed tomography, each modality presenting distinct sensitivity, spatial resolution, and tracer compatibility trade-offs that shape study design.

Applications drive technical requirements and purchasing logic, as cardiology, drug development, immunology & inflammation, infectious diseases, neurology, and oncology each impose unique endpoint definitions, throughput expectations, and validation needs. End users consolidate the demand side; academic and research institutes prioritize flexibility and methodological transparency, contract research organizations emphasize throughput, reproducibility, and regulatory-grade documentation, and pharmaceutical and biotechnology companies focus on translational relevance, data integration with clinical biomarkers, and vendor accountability. Integrating these segmentation layers yields a nuanced framework for product positioning, commercialization strategy, and prioritization of R&D investments.

Regional commercialization dynamics and differentiated adoption pathways across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape go-to-market strategy

Regional dynamics materially influence commercialization pathways and strategic priorities across preclinical imaging. In the Americas, investment in translational research infrastructure and a dense network of biotechnology hubs stimulates demand for high-throughput, regulatory-aligned services and advanced analytics, prompting vendors to emphasize service reliability and validation. Meanwhile, Europe, Middle East & Africa presents a heterogeneous landscape where regulatory diversity and varied healthcare funding models necessitate flexible commercial strategies; here, interoperability and local regulatory counsel are decisive factors for adoption.

In the Asia-Pacific region, rapid growth in research capacity, combined with expanding clinical trial activity, is driving appetite for scalable systems and cost-effective consumables, while local manufacturing partnerships and academic-industry collaborations are accelerating technology diffusion. Across these regions, differences in labor costs, regulatory timelines, and infrastructure maturity create distinct adoption curves for multimodal platforms versus standalone systems, and they shape where companies prioritize field trials, partnerships, and localized support networks. Understanding these regional contours is essential for aligning distribution strategies, customer education programs, and after-sales service models.

Competitive advantages derived from modular hardware, reagent precision, validated analytics, and integrated service models that drive customer retention

Key company-level insights reveal how strategic choices manifest across product portfolios, go-to-market approaches, and partnership models. Leading instrumentation providers are investing in modular architectures that allow incremental upgrades and multimodal integration, thereby protecting customer capital while enabling feature expansion. Reagent developers are concentrating on high-specificity contrast agents and radiotracers with improved stability and batch consistency, recognizing that reproducibility and regulatory documentation increasingly determine purchaser confidence.

Software and analytics firms are differentiating through validated algorithms, transparent performance metrics, and interoperability with common laboratory information management systems. On the commercial front, several companies are expanding service offerings to include application support, imaging biomarker qualification, and turnkey study execution, which appeals to sponsors seeking single-source accountability. Strategic partnerships between hardware vendors, reagent suppliers, and analytics providers are becoming more prevalent, enabling bundled offerings that reduce integration risk for end users. Ultimately, companies that align technical roadmaps with end-user workflows and regulatory expectations will secure stronger enterprise relationships and longer-term contracts.

Practical strategic priorities for vendors and purchasers to strengthen supply resilience, modular integration, regulatory alignment, and partnership-driven adoption

Industry leaders can accelerate impact by adopting a set of pragmatic, high-return actions focused on resilience, collaboration, and customer-centric design. First, reassess supply chain architecture to incorporate dual sourcing, regional assembly, and safety stock policies that mitigate the operational effects of trade disruptions and component scarcity. Second, prioritize modular product roadmaps and open integration standards to reduce customer lock-in barriers and enable seamless multimodal workflows that align with laboratory needs.

Third, invest in regulatory and validation support services that help customers translate preclinical imaging biomarkers into clinically relevant endpoints; such services increase perceived vendor value and shorten adoption cycles. Fourth, design commercial models that combine capital flexibility with outcome-oriented service tiers, thereby addressing diverse buyer risk profiles. Fifth, cultivate partnerships with academic centers and CROs to co-develop protocols and generate reproducibility evidence that underpins commercial claims. By implementing these targeted measures, organizations can strengthen competitive differentiation, protect operational continuity, and accelerate technology adoption across the ecosystem.

A mixed-methods approach combining expert interviews, technology benchmarking, and triangulated secondary sources to derive practical and validated insights

The research methodology underpinning this analysis blends qualitative expert interviews, technology benchmarking, and triangulated secondary research to ensure a robust evidentiary foundation. Subject-matter experts including instrument engineers, reagent chemists, imaging scientists, and procurement leads informed the interpretation of modality-specific trade-offs and adoption drivers. Technology benchmarking compared system specifications, reagent profiles, and analytical capabilities to identify patterns of convergence and differentiation.

Secondary sources included peer-reviewed literature, clinical translation case studies, regulatory guidance documents, and publicly available technical specifications from manufacturers, which were synthesized to validate trends and to identify areas of consensus versus emerging debate. Throughout the process, findings were cross-checked against practitioner feedback to surface practical implications for study design, procurement, and commercialization. This mixed-methods approach balances technical rigor with market relevance and supports the actionable recommendations provided in this summary.

Synthesizing actionable conclusions that connect technological convergence, operational resilience, and regulatory alignment to advance translational preclinical imaging

In closing, preclinical imaging stands at a pivotal juncture where technological maturity, reagent sophistication, and advanced analytics converge to accelerate translational impact. Stakeholders who adapt through strategic supply chain redesign, modular technology adoption, and strengthened validation pathways will capture disproportionate value as the ecosystem shifts toward integrated, reproducible workflows. Moreover, regional differences emphasize the need for tailored commercialization strategies that respect regulatory diversity and operational realities.

As the market evolves, the organizations that integrate scientific innovation with pragmatic commercialization practices-such as scalable service offerings, partnership-driven protocol development, and clear regulatory engagement plans-will lead adoption and sustain long-term relationships with end users. The insights presented here are designed to inform those strategic choices and to provide a foundation for immediate actions that protect study continuity and enhance translational outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence for automated lesion detection and biomarker extraction in preclinical MRI
  • 5.2. Development of high-speed volumetric ultrasound imaging systems for real-time vascular assessment in small animal models
  • 5.3. Adoption of hybrid PET/MRI platforms for simultaneous functional and anatomical imaging in oncology research
  • 5.4. Implementation of 3D micro-CT imaging with contrast agents for longitudinal bone density and vascular studies in rodent models
  • 5.5. Advancements in fluorescence molecular tomography enabling deep tissue imaging and quantitative fluorescent probe analysis
  • 5.6. Use of photoacoustic imaging combined with ultrasound to monitor tumor oxygenation and vascular changes dynamically
  • 5.7. Standardization of image acquisition protocols and data normalization workflows to enhance reproducibility across preclinical sites

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Preclinical Imaging Market, by Product

  • 8.1. Reagents
    • 8.1.1. Bioluminescent Imaging Reagents
    • 8.1.2. Fluorescent Imaging Reagents
    • 8.1.3. MRI Contrasting Reagents
    • 8.1.4. PET Radioactive Tracers
    • 8.1.5. Ultrasound Contrasting Reagents
    • 8.1.6. X-ray CT Contrasting Reagents
  • 8.2. Software & Services

9. Preclinical Imaging Market, by Type

  • 9.1. Multimodal Systems
  • 9.2. Standalone Imaging Systems

10. Preclinical Imaging Market, by Imaging Modality

  • 10.1. Magnetic Particle Imaging
  • 10.2. Magnetic Resonance Imaging
  • 10.3. Micro-Computed Tomography
  • 10.4. Optical Imaging
  • 10.5. Positron Emission Tomography
  • 10.6. Single-Photon Emission Computed Tomography

11. Preclinical Imaging Market, by Applications

  • 11.1. Cardiology
  • 11.2. Drug Development
  • 11.3. Immunology & Inflammation
  • 11.4. Infectious Diseases
  • 11.5. Neurology
  • 11.6. Oncology

12. Preclinical Imaging Market, by End Users

  • 12.1. Academic & Research Institutes
  • 12.2. Contract Research Organizations
  • 12.3. Pharmaceutical & Biotechnology Companies

13. Preclinical Imaging Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Preclinical Imaging Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Preclinical Imaging Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Advanced Molecular Vision, Inc.
    • 16.3.2. Agilent Technologies, Inc.
    • 16.3.3. Angstrom Advanced Inc.
    • 16.3.4. Aspect Imaging Ltd.
    • 16.3.5. AXT Pty Ltd
    • 16.3.6. Berthold Technologies
    • 16.3.7. Bruker Corporation
    • 16.3.8. Cubresa, Inc.
    • 16.3.9. Euro-BioImaging ERIC
    • 16.3.10. FUJIFILM Holdings America Corporation
    • 16.3.11. GE HealthCare Technologies Inc.
    • 16.3.12. IVIM Technology Corp.
    • 16.3.13. KUB Technologies, Inc.
    • 16.3.14. LI-COR, Inc.
    • 16.3.15. Mediso Ltd.
    • 16.3.16. Milabs B.V.
    • 16.3.17. Miltenyi Biotec GmbH
    • 16.3.18. MR Solutions Ltd.
    • 16.3.19. Peira bvba
    • 16.3.20. PerkinElmer Inc.
    • 16.3.21. Revvity, Inc.
    • 16.3.22. Scitech Pty Ltd
    • 16.3.23. Siemens AG
    • 16.3.24. TriFoil Imaging
    • 16.3.25. United Imaging Healthcare Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PRECLINICAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. PRECLINICAL IMAGING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. PRECLINICAL IMAGING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PRECLINICAL IMAGING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PRECLINICAL IMAGING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PRECLINICAL IMAGING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY BIOLUMINESCENT IMAGING REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY BIOLUMINESCENT IMAGING REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY BIOLUMINESCENT IMAGING REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY BIOLUMINESCENT IMAGING REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY BIOLUMINESCENT IMAGING REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY BIOLUMINESCENT IMAGING REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY FLUORESCENT IMAGING REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY FLUORESCENT IMAGING REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY FLUORESCENT IMAGING REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY FLUORESCENT IMAGING REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY FLUORESCENT IMAGING REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY FLUORESCENT IMAGING REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MRI CONTRASTING REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MRI CONTRASTING REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MRI CONTRASTING REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MRI CONTRASTING REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MRI CONTRASTING REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MRI CONTRASTING REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PET RADIOACTIVE TRACERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PET RADIOACTIVE TRACERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PET RADIOACTIVE TRACERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PET RADIOACTIVE TRACERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PET RADIOACTIVE TRACERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PET RADIOACTIVE TRACERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ULTRASOUND CONTRASTING REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ULTRASOUND CONTRASTING REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ULTRASOUND CONTRASTING REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ULTRASOUND CONTRASTING REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ULTRASOUND CONTRASTING REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ULTRASOUND CONTRASTING REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY X-RAY CT CONTRASTING REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY X-RAY CT CONTRASTING REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY X-RAY CT CONTRASTING REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY X-RAY CT CONTRASTING REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY X-RAY CT CONTRASTING REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY X-RAY CT CONTRASTING REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MULTIMODAL SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MULTIMODAL SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MULTIMODAL SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MULTIMODAL SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MULTIMODAL SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MULTIMODAL SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY STANDALONE IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY STANDALONE IMAGING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY STANDALONE IMAGING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY STANDALONE IMAGING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY STANDALONE IMAGING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY STANDALONE IMAGING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC PARTICLE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC PARTICLE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC PARTICLE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC PARTICLE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC PARTICLE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC PARTICLE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MICRO-COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MICRO-COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MICRO-COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MICRO-COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MICRO-COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MICRO-COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY OPTICAL IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY OPTICAL IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY OPTICAL IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY OPTICAL IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY OPTICAL IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY OPTICAL IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY DRUG DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY DRUG DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY DRUG DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY DRUG DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 286. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 287. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 288. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 297. GCC PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GCC PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GCC PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 300. GCC PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 301. GCC PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 302. GCC PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 303. GCC PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. GCC PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. GCC PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 306. GCC PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 307. GCC PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 308. GCC PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 309. GCC PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 310. GCC PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY IMAG